| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseDiscovery | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Cardiovascular Diseases | Discovery | - | 05 Jun 2025 | |
| Congenital Disorders | Discovery | - | 05 Jun 2025 | |
| Digestive System Disorders | Discovery | - | 05 Jun 2025 | |
| Ear Diseases | Discovery | - | 05 Jun 2025 | |
| Endocrinology and Metabolic Disease | Discovery | - | 05 Jun 2025 | |
| Eye Diseases | Discovery | - | 05 Jun 2025 | |
| Hemic and Lymphatic Diseases | Discovery | - | 05 Jun 2025 | |
| Immune System Diseases | Discovery | - | 05 Jun 2025 | |
| Infectious Diseases | Discovery | - | 05 Jun 2025 | |
| Neoplasms | Discovery | - | 05 Jun 2025 | 





